Indaptus Therapeutics, Inc. Payments to Acquire Marketable Securities
Indaptus Therapeutics, Inc. (INDP) reported Payments to Acquire Marketable Securities of $6.86 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-03-13
- Indaptus Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2023-03-31 was $6.86M, a 130.90% increase year-over-year.
- Indaptus Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $6.86M, a 76.83% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $29.60M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $6.86M 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $6.86M 10-Q · filed 2024-11-12 | $12.74M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $6.86M 10-Q · filed 2024-08-12 | $12.74M derived: sum of 3 quarters · filed 2024-08-12 | $17.68M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $6.86M 10-Q · filed 2024-05-08 | $12.74M derived: sum of 2 quarters · filed 2024-05-08 | $17.68M derived: sum of 3 quarters · filed 2024-05-08 | $33.49M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $10.82M derived: sum of 2 quarters · filed 2024-03-13 | $26.63M derived: sum of 3 quarters · filed 2024-03-13 | $29.60M 10-K · filed 2024-03-13 |
| 2022-09-30 | $4.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $20.75M derived: sum of 2 quarters · filed 2023-11-06 | $23.72M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $15.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $18.78M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $2.97M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |